Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248272 | 0.87 | MEN1 (0.51) | MEN1KMT2AMEP1BKDM4E | |
| SCHEMBL2242517 | 0.86 | FFAR1 (0.51) | — | |
| SCHEMBL2250511 | 0.84 | MEN1 (0.47) | MEN1KMT2APDCD1CD274KDM4E | |
| SCHEMBL2247297 | 0.84 | TACR1 (0.43) | TACR1MEN1KMT2AHIF1APDCD1 | |
| SCHEMBL2249856 | 0.82 | ALDH1A1 (0.52) | MEN1KMT2AMEP1B | |
| SCHEMBL2245581 | 0.79 | MEP1B (0.43) | MEP1BPTPN1HPGDS | |
| SCHEMBL2248442 | 0.79 | TAS1R3 (0.50) | MEN1KMT2APDCD1CD274LMNA | |
| SCHEMBL2249530 | 0.78 | HDAC1 (0.49) | MEN1KMT2AKDM4E | |
| SCHEMBL2251929 | 0.77 | MEP1B (0.52) | MEP1BHPGDS | |
| SCHEMBL8804625 | 0.77 | MAOA (0.53) | TACR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | TACR1 703/4885MEN1 2734/4885KMT2A 2364/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | TACR1 703/4885MEN1 2734/4885KMT2A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.